Details

Autor(en) / Beteiligte

• Zhang, Shanshan
• Song, Xinhua
• Cao, Dan
• Xu, Zhong
• Fan, Biao
• Che, Li
• Hu, Junjie
• Chen, Bin
• Dong, Mingjie
• Pilo, Maria G.
• Cigliano, Antonio
• Evert, Katja
• Ribback, Silvia
• Dombrowski, Frank
• Pascale, Rosa M.
• Cossu, Antonio
• Vidili, Gianpaolo
• Porcu, Alberto
• Simile, Maria M.
• Pes, Giovanni M.
• Giannelli, Gianluigi
• Gordan, John
• Wei, Lixin
• Evert, Matthias
• Cong, Wenming
• Calvisi, Diego F.
• Chen, Xin

Titel

Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice

Ist Teil von

• Journal of hepatology, 2017-12, Vol.67 (6), p.1194-1203

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Elsevier ScienceDirect Journals Complete

Beschreibungen/Notizen

• [Display omitted] •A novel mouse model of intrahepatic cholangiocarcinoma (ICC) was established.•Hydrodynamic transfection of activated forms of AKT and Yap was used to induce ICC.•This model recapitulates many morphological and molecular features of human ICC.•MLN0128 may be superior to gemcitabine/oxaliplatin based chemotherapy to treat ICC.•The efficacy of MLN0128 is mainly attributed to induction of apoptosis of ICC cells. Intrahepatic cholangiocarcinoma (ICC) is a lethal malignancy without effective treatment options. MLN0128, a second generation pan-mTOR inhibitor, shows efficacy for multiple tumor types. We evaluated the therapeutic potential of MLN0128 vs. gemcitabine/oxaliplatin in a novel ICC mouse model. We established a novel ICC mouse model via hydrodynamic transfection of activated forms of AKT (myr-AKT) and Yap (YapS127A) protooncogenes (that will be referred to as AKT/YapS127A). Genetic approaches were applied to study the requirement of mTORC1 and mTORC2 in mediating AKT/YapS127A driven tumorigenesis. Gemcitabine/oxaliplatin and MLN0128 were administered in AKT/YapS127A tumor-bearing mice to study their anti-tumor efficacy in vivo. Multiple human ICC cell lines were used for in vitro experiments. Hematoxylin and eosin staining, immunohistochemistry and immunoblotting were applied for the characterization and mechanistic study. Co-expression of myr-AKT and YapS127A promoted ICC development in mice. Both mTORC1 and mTORC2 complexes were required for AKT/YapS127A ICC development. Gemcitabine/oxaliplatin had limited efficacy in treating late stage AKT/YapS127A ICC. In contrast, partial tumor regression was achieved when MLN0128 was applied in the late stage of AKT/YapS127A cholangiocarcinogenesis. Furthermore, when MLN0128 was administered in the early stage of AKT/YapS127A carcinogenesis, it led to disease stabilization. Mechanistically, MLN0128 efficiently inhibited AKT/mTOR signaling both in vivo and in vitro, inducing strong ICC cell apoptosis and only marginally affecting proliferation. This study suggests that mTOR kinase inhibitors may be beneficial for the treatment of ICC, even in tumors that are resistant to standard of care chemotherapeutics, such as gemcitabine/oxaliplatin-based regimens, especially in the subset of tumors exhibiting activated AKT/mTOR cascade. Lay summary: We established a novel mouse model of intrahepatic cholangiocarcinoma (ICC). Using this new preclinical model, we evaluated the therapeutic potential of mTOR inhibitor MLN0128 vs. gemcitabine/oxaliplatin (the standard chemotherapy for ICC treatment). Our study shows the anti-neoplastic potential of MLN0128, suggesting that it may be superior to gemcitabine/oxaliplatin-based chemotherapy for the treatment of ICC, especially in the tumors exhibiting activated AKT/mTOR cascade.